No products in the cart.
ADHD Combination Asset
Triple Reuptake Inhibitor
Stage:NDA Submitted
A triple reuptake inhibitor for ADHD, non-controlled and non-doping, addressing abuse risk, dose-response variability, and the emotional dimension gap of current therapies.
- Non-controlled formulation
- Non-doping compliant
- Addresses abuse risk
- Fills emotional dimension gap
Target Launch:NDA in Review


